Cipher Pharmaceuticals Inc announced the Canadian launch of OZANEX™ (ozenoxacin cream, 1%), a novel bactericidal topical antibiotic cream indicated for the treatment of impetigo in patients aged 2 months and older.
OZANEX can be used to cure one of the most common and contagious bacterial skin infections. It can be utilised as a new and important treatment alternative for skin infections.
The novel bactericidal topical antibiotic cream is capable to fulfill all unmet medical needs due to its effectiveness against a broad range of bacteria including sensitive and resistant bacteria such as MRSA.
OAZANEX has showcased excellent antibacterial activity against Streptococcus pyogenes and Staphylococcus aureus, including methicillin-resistant (MRSA) strains in two Phase III pivotal studies involving 875 adult and pediatric subjects.
It has shown short 5-day BID dosing regimen and bacteriological eradication as early as day three of treatment.
After conducting few tests, OZANEX was found to be negligibly absorbed, safe, and well-tolerated in pediatric and adult patients aged 2 months and older.
OZANEX, a fast, effective and safe new treatment option kills bacteria quickly offering patients the shortest course of topical antibiotic treatment.
